Aberdeen Group plc grew its stake in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 17.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 661,416 shares of the biopharmaceutical company's stock after purchasing an additional 98,191 shares during the quarter. Aberdeen Group

Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $48.33, for a total transaction of $1,681,449.03. Following the transaction, the chief financial officer owned 32,916 shares of the company's stock,

Royalty Pharma said on Monday it has signed a $500 ​million research and development agreement ‌with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.

SG Americas Securities LLC lifted its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 438.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,202 shares of the biopharmaceutical company's stock after purchasing an additional 234,629 shares during the

Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $45.53, for a total transaction of $1,584,034.23. Following the completion of the transaction, the chief financial officer owned 43,886

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma.

Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments

Elo Mutual Pension Insurance Co lifted its position in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 57.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,984 shares of the biopharmaceutical company's stock after acquiring an additional

Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript